These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 2900291)

  • 21. 3-O-methyl-DOPA is not involved in the development of behavioral supersensitivity after repeated L-dopa administration in 6-OHDA lesioned rats.
    Bräutigam K; Sohr R; Morgenstern R
    Behav Brain Res; 1994 Jul; 63(1):41-5. PubMed ID: 7945976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK; Banerji T; Jenner P; Marsden CD
    Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autoradiographic study of striatal dopamine re-uptake sites and dopamine D1 and D2 receptors in a 6-hydroxydopamine and quinolinic acid double-lesion rat model of striatonigral degeneration (multiple system atrophy) and effects of embryonic ventral mesencephalic, striatal or co-grafts.
    Puschban Z; Scherfler C; Granata R; Laboyrie P; Quinn NP; Jenner P; Poewe W; Wenning GK
    Neuroscience; 2000; 95(2):377-88. PubMed ID: 10658617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential involvement of dopamine D-1 and D-2 receptors in the circling behaviour induced by apomorphine, SK & F 38393, pergolide and LY 171555 in 6-hydroxydopamine-lesioned rats.
    Arnt J; Hyttel J
    Psychopharmacology (Berl); 1985; 85(3):346-52. PubMed ID: 2860689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of normal and supersensitive dopamine receptors: effects of ergot drugs and neuropeptides.
    Fuxe K; Agnati LF; Köhler C; Kuonen D; Ogren SO; Andersson K; Hökfelt T
    J Neural Transm; 1981; 51(1-2):3-37. PubMed ID: 7264628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.
    Kääriäinen TM; García-Horsman JA; Piltonen M; Huotari M; Männistö PT
    Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):300-7. PubMed ID: 17973898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
    Hossain MA; Weiner N
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 7-[3-(4-[2,3-Dimethylphenyl]piperazinyl)propoxy]-2(1H)-quinolinone (OPC-4392), a presynaptic dopamine autoreceptor agonist and postsynaptic D2 receptor antagonist.
    Yasuda Y; Kikuchi T; Suzuki S; Tsutsui M; Yamada K; Hiyama T
    Life Sci; 1988; 42(20):1941-54. PubMed ID: 3130534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats.
    Treseder SA; Rose S; Jenner P
    Eur J Neurosci; 2001 Jan; 13(1):162-70. PubMed ID: 11135014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Carbidopa-based modulation of the functional effect of the AAV2-hAADC gene therapy in 6-OHDA lesioned rats.
    Ciesielska A; Sharma N; Beyer J; Forsayeth J; Bankiewicz K
    PLoS One; 2015; 10(4):e0122708. PubMed ID: 25860990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bromocriptine holiday: effects on dopamine receptors and turning behavior in rats.
    Kenny AM; Schneider MB; Baden DR; Pfeiffer RF; Murrin LC
    Neurology; 1986 Mar; 36(3):400-4. PubMed ID: 3081831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined administration of direct dopamine receptor agonists and L-dopa does not interfere with utilization of exogenous L-dopa in rat corpus striatum.
    Globus M; Melamed E
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(2-3):211-5. PubMed ID: 6310691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys.
    Falardeau P; Bouchard S; Bédard PJ; Boucher R; Di Paolo T
    Eur J Pharmacol; 1988 May; 150(1-2):59-66. PubMed ID: 3261249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The dopamine-gamma aminobutyric acid interaction in the striatum of the rat is differently regulated by dopamine D-1 and D-2 types of receptor: evidence obtained with rotational behavioural experiments.
    Herrera-Marschitz M; Ungerstedt U
    Acta Physiol Scand; 1987 Mar; 129(3):371-80. PubMed ID: 3033996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Behavioural and biochemical changes following chronic administration of L-dopa to rats.
    Pycock C; Dawbarn D; O'Shaughnessy C
    Eur J Pharmacol; 1982 Apr; 79(3-4):201-15. PubMed ID: 7201400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of repeated administration of l-DOPA and apomorphine on circling behavior and striatal dopamine formation.
    Brannan T; Prikhojan A; Yahr MD
    Brain Res; 1998 Feb; 784(1-2):148-53. PubMed ID: 9518585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential ability of selective and non-selective dopamine agonists to induce climbing in the rat indicates the involvement of both D-1 and D-2 receptors in this behaviour.
    Davis A; Jenner P; Marsden CD
    Psychopharmacology (Berl); 1990; 100(1):19-26. PubMed ID: 1967499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ketotifen can antagonise changes in sensitivity of cerebral dopamine receptors: behavioural correlates in rodent and primate.
    Barnes JC; Barnes NJ; Barnes NM; Costall B; Domeney AM; Naylor RJ
    Neuropharmacology; 1987 Jul; 26(7A):693-700. PubMed ID: 3114665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA.
    Johnson AM; Loew DM; Vigouret JM
    Br J Pharmacol; 1976 Jan; 56(1):59-68. PubMed ID: 943193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.